DNLI:NASDAQ, Denali Therapeutics Inc.

DNLI stock overview

Denali Therapeutics Inc. (DNLI:NASDAQ) closed at $18.41 on October 23, 2026, down 1.34% on the day. The stock trades 32.6% below its 52-week high of $27.30 and 33.9% above its 52-week low of $13.75. Over the past year, it gained 15.4%. Denali Therapeutics Inc. is part of the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)).

Key figures

Price: $18.41
Day change: -1.34%
Volume: 1,005,556
Average volume: 1,590,171
Market cap: 2B+
52-week range: $13.75 – $27.30
50-day average: $21.33
200-day average: $21.19

Price action over the past year

In 252 trading sessions since October 23, 2025, DNLI closed higher on 118 days (47%). Its best day was November 11, 2025 (+12.69%) and its worst was July 14, 2026 (-14.46%). The stock moved 10% or more in a single session 5 times. It opened at least 5% above the previous day's high 1 time.

Recent signals

Oct 23, 2026: Trading sideways between $17.61 and $18.95 over 14 days (Sideways scanner)
Oct 22, 2026: News catalyst: Earnings (News Catalysts scanner)

DNLI news

Oct 22, 2026: Denali Therapeutics to Report Third Quarter 2026 Financial Results and Business Highlights on November 3, 2026
Oct 14, 2026: Can RARE's Approved Product Portfolio Drive Its Next Growth Phase?
Oct 13, 2026: Pompe Disease Market Set for Expansion During the Forecast Period (2026-2036) as Growth is Fueled by Next-Generation ERTs, Newborn Screening, and Pipeline Innovation | DelveInsight
Oct 10, 2026: Is Denali Therapeutics (DNLI) Reasonably Valued On Future Cash Flow?
Oct 9, 2026: Is Denali Therapeutics (DNLI) Undervalued As Its Share Price Pullback Tests Fair Value?
Aug 20, 2026: DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock?
Aug 20, 2026: Should You Buy, Sell or Hold Biogen Stock After a 9% Rise in a Month?
Aug 13, 2026: Denali Therapeutics (DNLI) Q2 2026 Earnings Call Transcript

About Denali Therapeutics Inc.

Denali Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing therapeutics for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis.

Similar stocks

Find more stocks like DNLI with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.